Living cells are decreased in the PDL on the pressure side of a Pn−/− molar tooth subjected to experimental tooth movement. by Hideyuki Tanabe (243557)

Decreased remyelination initiation is observed in Scribble cKO mice following focal demyelination in corpus callosum. by Andrew A. Jarjour (343100)

“…<i>n</i> = 3 mice per genotype. * <i>p</i> < 0.05, ** <i>p</i> < 0.01, *** <i>p</i> < 0.001 versus Scrib WT CL. Scale bars: A,B,D,E: 2 μm. J,K: 50 μm.</p>…”

Supplementary Material for: Use of the Myocardial Performance Index in Decreased Fetal Movement Assessment: A Case-Control Study by Ho D. (4108837)

“…<p><b><i>Objectives:</i></b> To determine whether there are any fetal cardiac function changes, as measured by the myocardial performance index (MPI), in pregnancies complicated by decreased fetal movement (DFM). <b><i>Methods:</i></b> We performed a prospective cross-sectional case-control study of 50 DFM and 50 uncomplicated third-trimester pregnancies matched within 2 gestational weeks. …”

Example of inflection points estimated with a window size of 5. by Taiga Mori (21410076)

Representation of better of the two eyes’ monocular FMTs and binocular FMTs. by C. Vijay Reena Durai (14498259)

Subjects:

Binocular summation ratio. by C. Vijay Reena Durai (14498259)

Subjects:

Representation of better of the two eyes’ monocular FMTs and binocular FMTs. by C. Vijay Reena Durai (14498259)

Subjects:

S1 File - by C. Vijay Reena Durai (14498259)

Subjects:

WNF decreases Aβ peptides generation in HEK293 and SH-SY5Y human cells. by Htut Htut Htoo (3686641)

Autophagy is decreased at later time points post-infection in human macrophages. by Grant R. Campbell (298586)

6:2 Chlorinated Polyfluoroalkyl Ether Sulfonate (F-53B) Induces Aging and Parkinson’s Disease-like Disorders in <i>C. elegans</i> at Low Concentrations by Hui Li (32376)

“…After exposure to F-53B at 2, 10, and 50 ng/L, C. elegans showed an aging phenomenon as lipofuscin was significantly increased by 48.7–57.5% and locomotion, such as center point speed, was significantly decreased in all exposure groups. …”

6:2 Chlorinated Polyfluoroalkyl Ether Sulfonate (F-53B) Induces Aging and Parkinson’s Disease-like Disorders in <i>C. elegans</i> at Low Concentrations by Hui Li (32376)

“…After exposure to F-53B at 2, 10, and 50 ng/L, C. elegans showed an aging phenomenon as lipofuscin was significantly increased by 48.7–57.5% and locomotion, such as center point speed, was significantly decreased in all exposure groups. …”

6:2 Chlorinated Polyfluoroalkyl Ether Sulfonate (F-53B) Induces Aging and Parkinson’s Disease-like Disorders in <i>C. elegans</i> at Low Concentrations by Hui Li (32376)

“…After exposure to F-53B at 2, 10, and 50 ng/L, C. elegans showed an aging phenomenon as lipofuscin was significantly increased by 48.7–57.5% and locomotion, such as center point speed, was significantly decreased in all exposure groups. …”

6:2 Chlorinated Polyfluoroalkyl Ether Sulfonate (F-53B) Induces Aging and Parkinson’s Disease-like Disorders in <i>C. elegans</i> at Low Concentrations by Hui Li (32376)

“…After exposure to F-53B at 2, 10, and 50 ng/L, C. elegans showed an aging phenomenon as lipofuscin was significantly increased by 48.7–57.5% and locomotion, such as center point speed, was significantly decreased in all exposure groups. …”

E₅₀ values. by Junxia Zhou (14381598)

Tempol and L-NAME help prevent the decrease in F_max. by Travis L. Dutka (321984)

Terpenoids decrease single-channel activity of L-AChRs elicited by ACh. by Guillermina Hernando (553795)

Points represent regions where the cluster coefficient was significantly larger in HC compared to MCI, at sparsity level of 0.15. by Therese M. Gilligan (7460906)

PIN1 silencing leads to decreases in the protein levels of HIF-1α. by Hyeong-jun Han (846566)

“…E) ATRA decreases the expression of HIF-1α and PIN1 in HCT116/5xHRE-ODD-luc cells in dose-dependent manner. …”

Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%. by Joseph Kamgno (81039)

“…<p>Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.…”